AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31592997 — intervention group
Group type: EXPERIMENTAL
Intervention: On the Move (OTM) task-oriented intervention
Number of subjects: 107
Study 31592997 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care impairment-based exercise intervention (STD)
Number of subjects: 107
Study 31592997 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 107
Study 30316493 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral guided self-help program
Number of subjects: 149
Study 30316493 — intervention group
Group type: COMPARATOR
Intervention: Nonbehavioral guided self-help program
Number of subjects: 149
Study 26496418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear SIgA during URTI
Number of subjects: 40
Study 26496418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear SIgA the week before URS
Number of subjects: 40
Study 26496418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear SIgA secretion rate <5.5 μg·min(‐1)
Number of subjects: 40
Study 26496418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear SIgA secretion rate decrease >30%
Number of subjects: 40
Study 26496418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear SIgA secretion rate >5.5 μg·min(‐1) or no decrease of >30%
Number of subjects: 40
Study 26496418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear SIgA after exercise
Number of subjects: 40
Study 26496418 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva flow rate after exercise and during dehydration
Number of subjects: 40
Study 26496418 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva SIgA concentration after exercise and during dehydration
Number of subjects: 40
Study 23230962 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 0
Study 23230962 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding promotion
Number of subjects: 0
Study 21848963 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocytapheresis
Number of subjects: 38
Study 21848963 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 38
Study 19823859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingerstall packs filled with gauze and smeared with vaseline (group 1)
Number of subjects: 48
Study 19823859 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon septal splint packs (group 2)
Number of subjects: 48
Study 19823859 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemostatic septal sutures (group 3)
Number of subjects: 48
Study 19823859 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 48
Study 18039020 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sertaconazole solution
Number of subjects: 313
Study 18039020 — intervention group
Group type: COMPARATOR
Intervention: 2% sertaconazole cream
Number of subjects: 313
Study 15738534 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course RT (8 Gy x 2 days)
Number of subjects: 300
Study 15738534 — intervention group
Group type: COMPARATOR
Intervention: Split-course RT (5 Gy x 3; 3 Gy x 5)
Number of subjects: 300
Study 12496749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily for 3 days
Number of subjects: 10
Study 12496749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9794174 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of exposure to p,p'‐DDE
Number of subjects: 180
Study 9794174 — intervention group
Group type: EXPERIMENTAL
Intervention: Total polychlorinated biphenyls (PCBs)
Number of subjects: 180
Study 9794174 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of exposure to organochlorine compounds
Number of subjects: 180
Study 8775841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatments for drug dependence
Number of subjects: 0
Study 2198314 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen of rifampin, isoniazid, dapsone, and clofazimine for the first 3 months and clofazimine plus dapsone for the next 57 months
Number of subjects: 0
Study 2198314 — intervention group
Group type: COMPARATOR
Intervention: Two-drug regimen of dapsone plus clofazimine for 60 months
Number of subjects: 0
Study 654409 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenalin (0.1 mg/kg bodyweight)
Number of subjects: 10
Study 654409 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (0.5 mg)
Number of subjects: 10
Study 31805025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Rehabilitation Education (TRE) program for 4 weeks
Number of subjects: 99
Study 31805025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TRE program)
Number of subjects: 99
Study 30536117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical Foley balloon catheter insertion adjunct to intravaginal PgE2 insert (n = 146)
Number of subjects: 294
Study 30536117 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal PgE2 vaginal insert alone (n = 148)
Number of subjects: 294
Study 28139456 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred Stenting (DS)
Number of subjects: 258
Study 28139456 — intervention group
Group type: COMPARATOR
Intervention: Immediate Stenting (IS)
Number of subjects: 258
Study 26217468 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Surgery (CAS)
Number of subjects: 57
Study 26217468 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 57
Study 23286418 — intervention group
Group type: EXPERIMENTAL
Intervention: Karate competitors (KC)
Number of subjects: 84
Study 23286418 — intervention group
Group type: COMPARATOR
Intervention: Exercise control (EC)
Number of subjects: 84
Study 21472103 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmin 500 mg for 1 week
Number of subjects: 86
Study 21472103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 19597718 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 191
Study 19597718 — intervention group
Group type: COMPARATOR
Intervention: Monarc
Number of subjects: 191
Study 19597718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 191
Study 16682681 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 48
Study 16682681 — intervention group
Group type: COMPARATOR
Intervention: Control (without voglibose)
Number of subjects: 48
Study 15139251 — intervention group
Group type: COMPARATOR
Intervention: Placebo as a comparative alternative
Number of subjects: 0
Study 15139251 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical arguments
Number of subjects: 0
Study 15139251 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution of moral conflicts
Number of subjects: 0
Study 15139251 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural safeguards
Number of subjects: 0
Study 11210397 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg tablet
Number of subjects: 7
Study 9256875 — intervention group
Group type: EXPERIMENTAL
Intervention: Father-focused discussion perinatal classes
Number of subjects: 0
Study 9256875 — intervention group
Group type: COMPARATOR
Intervention: Traditional childbirth classes
Number of subjects: 0
Study 8185742 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine i.v.
Number of subjects: 426
Study 8185742 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine i.v. + 10 mg metoclopramide i.v.
Number of subjects: 426
Study 8185742 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.3 M sodium citrate p.o.
Number of subjects: 426
Study 8185742 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.3 M sodium citrate p.o. + 10 mg metoclopramide i.v.
Number of subjects: 426
Study 3037863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotachysterol
Number of subjects: 50
Study 3037863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Number of subjects: 50
Study 3037863 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 50
Study 31262189 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine+phytosterol
Number of subjects: 253
Study 31262189 — intervention group
Group type: COMPARATOR
Intervention: nifedipine+placebo
Number of subjects: 253
Study 28488912 — intervention group
Group type: EXPERIMENTAL
Intervention: High ER activity profile (10.5% of patients)
Number of subjects: 969
Study 28488912 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen or letrozole treatment
Number of subjects: 969
Study 25944283 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiome analysis at 1 week of age
Number of subjects: 20
Study 25944283 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiome analysis at 1 month of age
Number of subjects: 20
Study 25944283 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiome analysis at 1 year of age
Number of subjects: 20
Study 25944283 — intervention group
Group type: COMPARATOR
Intervention: Maternal gut microbiome analysis
Number of subjects: 20
Study 23535978 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype threat condition
Number of subjects: 40
Study 23535978 — intervention group
Group type: COMPARATOR
Intervention: Nullified-stereotype condition
Number of subjects: 40
Study 21525688 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP mixed with β‐TCP
Number of subjects: 20
Study 21525688 — intervention group
Group type: COMPARATOR
Intervention: β‐TCP alone
Number of subjects: 20
Study 18029218 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT)
Number of subjects: 27
Study 18029218 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 16439507 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (n = 15)
Number of subjects: 28
Study 16439507 — intervention group
Group type: COMPARATOR
Intervention: HCG (n = 13)
Number of subjects: 28
Study 16439507 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 28
Study 16439507 — intervention group
Group type: COMPARATOR
Intervention: HCG
Number of subjects: 28
Study 14722348 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregated locomotor function (ALF) score
Number of subjects: 214
Study 11284801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained smokers
Number of subjects: 734
Study 11284801 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 734
Study 9133992 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine reversal of heparin
Number of subjects: 64
Study 9133992 — intervention group
Group type: COMPARATOR
Intervention: No reversal of heparin
Number of subjects: 64
Study 7958040 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical flurbiprofen 0.03%
Number of subjects: 0
Study 7958040 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2844340 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV hyperimmune plasma (200 mg/kg body weight, given on four occasions during 2 days from day 3 to day 76 after transplantation)
Number of subjects: 54
Study 2844340 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 54
Study 2844340 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV hyperimmune plasma
Number of subjects: 54
Study 28885510 — intervention group
Group type: EXPERIMENTAL
Intervention: PD with pylorus preservation (PP)
Number of subjects: 188
Study 28885510 — intervention group
Group type: COMPARATOR
Intervention: PD with pylorus resection (PR)
Number of subjects: 188
Study 27642131 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antihelminthic treatment (albendazole)
Number of subjects: 185
Study 27642131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 25176152 — intervention group
Group type: EXPERIMENTAL
Intervention: AccuVein
Number of subjects: 266
Study 25176152 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 266
Study 23343840 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation with characteristic smoke and odor (intervention group, n = 52)
Number of subjects: 103
Study 23343840 — intervention group
Group type: COMPARATOR
Intervention: No smoke or odor (control group, n = 51)
Number of subjects: 103
Study 20089082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone citrate (TC) 30 mg/day for 4 weeks
Number of subjects: 37
Study 20089082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37
Study 18759315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment (specialized hands-on exercise training with muscle strengthening)
Number of subjects: 1234
Study 18759315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 1234
Study 18759315 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 1234
Study 12643400 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating heart surgery with RVAD
Number of subjects: 60
Study 12643400 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating heart surgery (off-pump)
Number of subjects: 60
Study 12643400 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery with CPB
Number of subjects: 60
Study 9672516 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline/furosemide on day 1
Number of subjects: 24
Study 9672516 — intervention group
Group type: COMPARATOR
Intervention: Placebo/furosemide on day 1
Number of subjects: 24
Study 9672516 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline enhancement of furosemide's effect
Number of subjects: 24
Study 9672516 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal function
Number of subjects: 24
Study 8040776 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin added to parenteral alimentation solution (25 micrograms per milliliter)
Number of subjects: 70
Study 2567667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2567667 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (propranolol, metoprolol, oxprenolol)
Number of subjects: 8
Study 1116100 — intervention group
Group type: COMPARATOR
Intervention: megavoltage extended field radiotherapy alone
Number of subjects: 87
Study 1116100 — intervention group
Group type: EXPERIMENTAL
Intervention: megavoltage radiotherapy limited to involved lymph node sites followed by combination chemotherapy (MOPP)
Number of subjects: 87
Study 31653157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphedema prevention protocol
Number of subjects: 120
Study 31653157 — intervention group
Group type: COMPARATOR
Intervention: Routine care (comparison group)
Number of subjects: 120
Study 28279499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (2.5, 10, 20, or 40mg)
Number of subjects: 0
Study 28279499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (40mg)
Number of subjects: 0
Study 28279499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20mg)
Number of subjects: 0
Study 28279499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25692792 — intervention group
Group type: EXPERIMENTAL
Intervention: Zagreb regimen (4 doses/3 visits) of purified chick embryo cell vaccine (PCECV)
Number of subjects: 250
Study 25692792 — intervention group
Group type: COMPARATOR
Intervention: Essen regimen (5 doses over 5 days) of purified chick embryo cell vaccine (PCECV)
Number of subjects: 250
Study 24019046 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 45
Study 24019046 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 45
Study 21664298 — intervention group
Group type: EXPERIMENTAL
Intervention: health maintenance intervention
Number of subjects: 392
Study 21664298 — intervention group
Group type: COMPARATOR
Intervention: control condition
Number of subjects: 392
Study 19268303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological interventions
Number of subjects: 5300
Study 19268303 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 5300
Study 19268303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Library systematic reviews
Number of subjects: 5300
Study 16959055 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS over the right prefrontal cortex
Number of subjects: 130
Study 16959055 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Hz rTMS over the right prefrontal cortex
Number of subjects: 130
Study 16959055 — intervention group
Group type: COMPARATOR
Intervention: 5-Hz left PFC rTMS
Number of subjects: 130
Study 16959055 — intervention group
Group type: COMPARATOR
Intervention: 10-Hz left PFC rTMS
Number of subjects: 130
Study 16959055 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 130
Study 15106887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 107
Study 15106887 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic‐behavioral-family therapy (SBFT)
Number of subjects: 107
Study 15106887 — intervention group
Group type: COMPARATOR
Intervention: Non‐directive‐supportive therapy (NST)
Number of subjects: 107
Study 10837944 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of goserelin and flutamide
Number of subjects: 2200
Study 10837944 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term hormonal therapy
Number of subjects: 2200
Study 9024957 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sodium valproate
Number of subjects: 7
Study 9024957 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg sodium valproate
Number of subjects: 7
Study 9024957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8345158 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine
Number of subjects: 0
Study 8345158 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 30136633 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs
Number of subjects: 105
Study 30136633 — intervention group
Group type: COMPARATOR
Intervention: csDMARDs
Number of subjects: 105
Study 29736609 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis (ciprofloxacin 500 mg B.I.D for 3 days)
Number of subjects: 496
Study 29736609 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented prophylaxis (ciprofloxacin + single preprocedure shot of 160 mg gentamicin IM)
Number of subjects: 496
Study 29736609 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted prophylaxis (rectal swab culture-based)
Number of subjects: 496
Study 26183465 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolisation (UAE) with Gelfoam
Number of subjects: 20
Study 26183465 — intervention group
Group type: COMPARATOR
Intervention: Uterine artery embolisation (UAE) with Embospheres
Number of subjects: 20
Study 25162447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of Sertraline, Mianserin, psycho-education, and Trauma-Focused Cognitive Behavioral Therapy (TFCBT)
Number of subjects: 0
Study 25162447 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (antidepressants)
Number of subjects: 0
Study 25162447 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 22569999 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive individuals
Number of subjects: 160
Study 22569999 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive individuals with poor ProM
Number of subjects: 160
Study 22569999 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 160
Study 20724806 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment initiation within 24 hours (early group)
Number of subjects: 62
Study 20724806 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet treatment initiation more than 24 hours (late group)
Number of subjects: 62
Study 20724806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 18482124 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Specialist Nurse prescriber intervention
Number of subjects: 56
Study 18482124 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention group (control)
Number of subjects: 56
Study 18482124 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention group (intervention)
Number of subjects: 56
Study 16517540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 37
Study 16517540 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 37
Study 12709518 — intervention group
Group type: EXPERIMENTAL
Intervention: Residency within 150-200 m from the composting site
Number of subjects: 356
Study 12709518 — intervention group
Group type: EXPERIMENTAL
Intervention: Residency in the highest bioaerosol exposure (150-200 m)
Number of subjects: 356
Study 12709518 — intervention group
Group type: COMPARATOR
Intervention: Unexposed controls (residency >400-500 m from the site)
Number of subjects: 356
Study 10921700 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (80 mg b.i.d.)
Number of subjects: 206
Study 10921700 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beta-blockade or antiarrhythmic drugs)
Number of subjects: 206
Study 8659783 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 MAC
Number of subjects: 24
Study 8659783 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 1.5 MAC
Number of subjects: 24
Study 8659783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 MAC
Number of subjects: 24
Study 8659783 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane, Halothane, Sevoflurane at 0.5 MAC
Number of subjects: 24
Study 1389826 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion during surgery
Number of subjects: 44
Study 1389826 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone infusion during surgery
Number of subjects: 44
Study 1389826 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion in ICU
Number of subjects: 44
Study 1389826 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone infusion in ICU
Number of subjects: 44
Study 4039433 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 150
Study 4039433 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 150